Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ZEPHYRUS; ZEPHYRUS-1
- Sponsors FibroGen
- 08 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2023 According to a FibroGen media release, company plans to communicate the results of the ZEPHYRUS-1 study at an upcoming medical forum.
- 26 Jun 2023 Primary endpoint (Change From Baseline in Forced Vital Capacity (FVC) at Week 48) has not been met as per FibroGen media release.